Hua Jian and Renhe Launch OTC Drug RWA Platform to Modernize Supply Chains

Harmony Medical (HKEX: 0370) has introduced that his affiliated Hua Jian Medical cooperates with Renhe Worldwide, a whole arm of Renhe Pharmaceutical, to construct a brand new Actual-World property (RWA) platform for over-the-counter (OTC) medicines.

The corporate is described as the primary vertical RWA system devoted to OTC medicines, with the purpose of streamlining provide chains and enhancing transparency in China’s quick -growing OTC market.

OTC medicines tokenizing for secure, real-time commerce

The challenge remains to be beneath improvement, however the corporations stated that the OTC pharmaceutical property will look, making secure, traceable and real-time transactions between producers, distributors and retailers potential.

By transferring drug shares and transactions to blockchain rails, the companions anticipate to decrease inefficiencies, decrease prices and enhance compliance with regulatory requirements, whereas market individuals get extra confidence in product authenticity.

Associated: RWA sector has a report of $ 25 billion worth, led by personal credit score and American treasury

Renhe’s position in technical infrastructure

Renhe Worldwide brings his background to digital transformation and blockchain acceptance for the initiative. The position is geared toward creating a scalable and secure technological infrastructure to help the platform.

Managers famous that the trouble displays the broader technique of Hua Jian to mix healthcare and expertise, particularly within the distribution layer the place bottlenecks and fraud dangers typically happen.

Why the OTC market of China issues

The OTC market of China is increasing in each city and rural areas, as a result of self-care and preventive drugs get a grip. Information within the trade quoted by the businesses recommend that this well being care phase can turn out to be a big development motor within the coming years.

By digitizing and tucking OTC drug flows, Hua Jian and Renhe need to speed up distribution, enhance responsiveness on demand shifts and cut back friction when supplying retail.

Implications within the trade

Analysts say that this partnership may turn out to be a mannequin for integrating RWAS into pharmaceutical provide chains, a sector that’s historically sluggish to adapt to digital innovation.

If profitable, the framework can affect how OTC medication usually are not solely traded in China, but additionally on worldwide care markets.

Associated: RWA Crypto sector emerges as Day’s Prime Performer with 6.9% revenue